{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiafvpfcw6e6sgvh5ly4g3qatlfkpqlchrzecycktwnbe4ojpqjjny",
    "uri": "at://did:plc:ox2kiwcr2xmn32p25g472pp7/app.bsky.feed.post/3mmp6unad3hd2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreieej3ovzdm6plqqgn673aylmxxcxipt4y2qnnl63hgzvwp2ugnmbi"
    },
    "mimeType": "image/webp",
    "size": 56334
  },
  "path": "/releases/2026/05/260525000453.htm",
  "publishedAt": "2026-05-25T09:39:26.000Z",
  "site": "https://www.sciencedaily.com",
  "textContent": "New NIH research reveals that semaglutide sparks different responses inside appetite-controlling brain cells, offering fresh insight into why GLP-1 weight-loss drugs don’t work the same for everyone. Scientists also found a possible way to extend the drugs’ effects, potentially helping patients push past weight-loss plateaus.",
  "title": "Scientists discover why Ozempic and Wegovy weight loss eventually plateaus"
}